Clinical Trials Browser

Phase NA × Recurrence × donafenib × Clear all

NCT06609876 2024-12-03

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

Phase NA Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence